DUBLIN--(BUSINESS WIRE)--The "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
The future market scenario looks promising for the research, development and commercial viability of small molecule based cancer drugs. The basic targeting advantage along with the dominance of small molecule drugs in cancer clinical pipeline will drive the global small molecule cancer drug market in coming years.
The market is expected to double its revenue to US$ 130 Billion by 2026 and will continue to outperform the others available drug therapies for the treatment of cancer malignancies.
Report Highlights:
- Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
- USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
- Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
- Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
- Small Molecule Drug Insight by Cancer
- Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
- Covid-19 Impact On Small Molecule Cancer Drug Market
An important parameter that should be associated with any of the cancer treatment is its specificity. Being specific to the cancer target is one of the most requisite and fundamental premise that decides whether the cancer therapy will result in inclination or declination of the mortality rate. The small molecule drug approach is quite specific and target oriented in functionality and has achieved interest of all stake holders from global cancer therapy market. The basic approach is to search for a specific molecular target and undergo the elimination of the cancer cells from the body. The small molecule cancer drug methodology is conceptually more specific than any of the available traditional non-targeted therapy as it provides a better target specificity and better reach to the cancer cells.
Small Molecule Based Cancer Drugs Account For More Than 25% Of The Global Cancer Drug Pipeline
As of now, small molecule drugs are considered as a special cancer therapy due to the advantages that are associated with it. In today's cancer therapeutics world, there are two therapies that undergo specific molecular targeting: monoclonal antibody and small molecule drugs. But there is also one parameter that is making small molecule drugs more preferable than the monoclonal antibodies is the size of small molecule drugs making it permeable to plasma membrane or cell membrane.
From the different studies that have been performed under the cancer research domain, it has been confirmed that in case of different cancer types, there are receptors for target that are present inside the cell membrane. The presence of target inside the cell membrane makes it difficult for other drugs to penetrate or target the desired receptor. At this position, the usage of small molecule drugs is necessary as it has the ability to cross the cell membrane due to small size and target the cancer receptor that is present inside the cell membrane.
Key Topics Covered:
1. Introduction to Small Drug Molecule
2. Need for Small Molecule Drug
3. Comparison of Cancer Small Molecule Drugs with Other Available Therapies
3.1 Small Molecule Cancer Drugs & its Comparison with Other Drugs Parameters
3.2 Small Molecule Cancer Drug vs. Immunotherapy
3.3 Small Molecule Cancer Drugs vs. Chemotherapy
3.4 Small Molecule Cancer Drug vs. Radiation Therapy
3.5 Small Molecule Cancer Drugs vs. Surgical Removal of Cancer Cells
4. Small Drug Molecule as Emerging Cancer Therapeutics
4.1 Small Molecule Drugs & its Relation with Cancer Treatment
4.2 Mechanisms Targeted by Small Molecule Drugs in Cancer Therapy
4.3 Small Molecule Inhibitors & their Related Pathways
5. Global Trends & Opportunities for Small Molecule Cancer Drug Market
5.1 US
5.2 Europe
5.3 Asia
5.4 Rest of World
6. Global Small Molecule Cancer Drug Clinical Pipeline Overview
6.1 By Phase
6.2 By Formulation
6.3 By Company
6.4 By Country
6.5 By Indication
6.6 By Mechanism of Action
7. Global Analysis for Small Molecule Cancer Drug Research Work at Educational Level
7.1 IACS-10759 Small Molecule Drug Discovery at MD Anderson
7.2 BET Small Molecule Inhibitor Discovery by Yale Researchers for the Cancer Patients
7.3 Amgen & Mirati's Small Molecule Cancer Drug against KRAS Gene in Different Cancer Types
7.4 AOH1160 Small Molecule Research to Focus Breast Cancer at University of California
8. Global Analysis for Partnerships, Collaborations for Expanding Small Molecule Cancer Drug Market
8.1 IACS & X-Chem to Undergo Small Molecule Cancer Therapies Development
8.2 MD Anderson, Artios Pharma & ShangPharma to Collaborate for Small Molecule ATR Inhibitor Program
8.3 Aptose Biosciences & Moffitt Cancer Center to Undergo Strategic Collaboration for the Development of New Multi-Targeting Epigenetic Therapeutic Agents
8.4 Merck & Taiho to Collaborate for Small KRAS- Targeting Cancer Drugs
9. Drivers & Challenges Associated with the Small Molecule Cancer Drug Market
9.1 Potential Insights about Factors Driving the Small Molecule Cancer Drug Market at Global Level
9.2 Challenges Concerning the Growth of Small Molecule Cancer Drug Market
10. Future Insights for Small Molecule Cancer Market in Cancer Research Area
11. Covid-19 Impact On Small Molecule Cancer Drug Market
12. Small Molecule Drugs for Breast Cancer - Availability, Dosage & Price Analysis
13. Small Molecule Drugs for Leukemia Cancer - Availability, Dosage & Price Analysis
14. Small Molecule Drugs for Lung Cancer - Availability, Dosage & Price Analysis
15. Small Molecule Drugs for Lymphomas - Availability, Dosage & Price Analysis
16. Small Molecule Drugs for Myeloma - Availability, Dosage & Price Analysis
17. Small Molecule Drugs for Prostate Cancer - Availability, Dosage & Price Analysis
18. Small Molecule Drugs for Gastric Cancer - Availability, Dosage & Price Analysis
19. Small Molecular Drugs For Cancer Diagnosis - Availability, Dosage & Price Analysis
20. Small Molecule Drugs for Skin Cancer - Availability, Dosage & Price Analysis
21. Small Molecule Drugs for Pancreatic Cancer - Availability, Dosage & Price Analysis
22. Small Molecule Drugs for Thyroid Tumors - Availability, Dosage & Price Analysis
23. Small Molecule Drugs for Renal Cancer - Availability, Dosage & Price Analysis
24. Small Molecule Drugs for Colorectum Cancer - Availability, Dosage & Price Analysis
25. Small Molecule Drugs for Solid Tumors - Availability, Dosage & Price Analysis
26. Small Molecule Drugs Targeting Multiple Cancer - Availability, Dosage, Price & Sales Analysis
27. Competitive Landscape
27.1 Johnson & Johnson
27.2 Teva Pharmaceutical
27.3 Boehringer Ingelheim
27.4 Allergan
27.5 Pfizer
27.6 Bristol-Myers Squibb
27.7 Merck
27.8 GlaxoSmithKline
27.9 AstraZeneca
27.10 Gilead Sciences
For more information about this report visit https://www.researchandmarkets.com/r/wmo4hv
